Akari Therapeutics

AKTX

Market cap $9.43M

Access the Akari CEO Corner  here

In-person presentation on Tuesday, January 13 th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari's ADC platform, strategic priorities and key milestones for 2026 TAMPA, Fla.

TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today issued the following letter to shareholders from its President and Chief Executive Officer, Abizer Gaslightwala.

Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work

Watch the “What This Means” video here

New cash portion of offering includes >20% participation from Directors, Officers and Executive Management New cash portion of offering includes >20% participation from Directors, Officers and Executive Management

Data highlights the ability of Akari's Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates

Access the Akari CEO Corner  here TAMPA, Fla. and LONDON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the publication of a new CEO Corner segment, now available on the Company's website.

Access the Akari CEO Corner  here BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the next CEO Corner segment has been published on the Company's website. For this CEO Corner segment, Abizer Gaslightwala, CEO of Akari, provides an overview of the Company's innovation in ADCs, highlighting its novel PH1 payload and its dual mechanism of action.

Akari Therapeutics, Plc ( AKTX ) Shareholder/Analyst Call November 18, 2025 11:00 AM EST Company Participants Abizer Gaslightwala - CEO, President & Director Satyajit Mitra - Executive Director & Head of Oncology Conference Call Participants Jenene Thomas Presentation Jenene Thomas Okay. We are ready to get started, and welcome, everyone, to the Akari Therapeutics Corporate Update Webcast.